Related Experiment Video

Updated: Aug 23, 2026

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

[Increased atria expression of receptor activity-modifying proteins in heart failure patients]

Yu-fang Wang1, Ji Zhang, Jing Li

  • 1School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, 610041 PR China.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics
|August 10, 2004
PubMed
Abstract

Insights

Heart failure involves changes in receptor activity-modifying proteins (RAMPs) and calcitonin gene related peptide (CGRP) and adrenomedullin (ADM) receptors. These alterations suggest a compensatory role for CGRP and ADM in chronic heart failure.

Area of Science:

  • Cardiovascular Biology
  • Molecular Endocrinology
  • Receptor Pharmacology

Context:

  • Receptor activity-modifying proteins (RAMPs) critically influence the ligand specificity of the calcitonin receptor-like receptor (CRLR).
  • Co-expression of RAMP1 with CRLR forms a calcitonin gene related peptide (CGRP) receptor, while RAMP2 or RAMP3 association with CRLR generates an adrenomedullin (ADM) receptor.
  • CGRP and ADM are implicated in potentially beneficial roles within the context of heart failure.

Purpose:

  • To investigate potential alterations in RAMP messenger RNA (mRNA) expression levels within the context of heart failure.
  • To determine if RAMP mRNA expression correlates with the severity of heart failure.

Summary:

  • Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) was employed to assess RAMP1 and RAMP3 mRNA expression in the atria of patients experiencing heart failure.
  • Results indicated an overall increase in RAMP1, RAMP2, and RAMP3 mRNA expression with worsening heart function.
  • However, a decrease in RAMP1 and RAMP2 mRNA expression was observed specifically at heart failure level IV.

Impact:

  • Demonstrated up-regulation of CGRP receptors (via RAMP1/CRLR) and ADM receptors (via RAMP2/CRLR) in the atria of heart failure patients.
  • Suggests that CGRP and ADM receptors play a functional role in the human body's compensatory mechanisms for chronic heart failure.
  • Provides molecular insights into the potential therapeutic targets for managing chronic heart failure.

More Related Videos

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...